NTRA

Natera Inc

310.67

Nov 06 • 3:59 PM ET -53.09 (-14.59%)

311.00

Aftermarket • 7:53 PM ET +0.33 (0.11%)

Healthcare Diagnostics & Research USA Large NASD

Nov 05, 6:38 PMNatera raises 2026 guidance and targets $6B 2029 revenue as MRD growth drives strong Q3 momentum

Peers: GH BLLN CDNA LH MYGN DGX NEO GRAL TEM CAI

| Held by: VTI VB VBK VXF IBB IWP IWR IWF XBI VHT

Scroll to Statements

Index	-
Market Cap	45.05B
Enterprise Value	44.19B
Income	-164.71M
Sales	2.91B
Book/sh	12.95
Cash/sh	7.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6140
IPO	Jul 02, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	15.49
P/B	23.99
P/C	41.06
P/FCF	858.56
EV/EBITDA	-
EV/Sales	15.19
Quick Ratio	2.66
Current Ratio	2.81
Debt/Eq	0.13
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-1.15
EPS next Y	-0.43
EPS next Q	-0.13
EPS this Y	-3.28%
EPS next Y	72.76%
EPS next 5Y	-
EPS past 3/5Y	35.09% 11.70%
Sales past 3/5Y	41.14% 42.61%
EPS Y/Y TTM	49.82%
Sales Y/Y TTM	37.43%
EPS Q/Q	34.82%
Sales Q/Q	34.08%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-49.47% 12.22%

Insider Own	6.42%
Insider Trans	-6.67%
Inst Own	92.63%
Inst Trans	0.97%
ROA	-7.21%
ROE	-10.55%
ROIC	-8.19%
Gross Margin	64.50%
Oper. Margin	-8.82%
Profit Margin	-5.66%
SMA20	-21.69%
SMA50	-18.30%
SMA200	15.34%
Trades

Shs Outstand	144.34M
Shs Float	134.88M
Short Float	4.34%
Short Ratio	3.56
Short Interest	5.85M
52W High	437.41 -28.97%
52W Low	181.00 71.64%
Volatility	7.54% 5.13%
ATR (14)	23.87
RSI (14)	28.53
Beta	1.55
Rel Volume	3.51
Avg Volume	1.65M
Volume	5,777,244

Perf Week	-25.01%
Perf Month	-20.50%
Perf Quarter	-2.41%
Perf Half Y	59.94%
Perf YTD	35.61%
Perf Year	56.52%
Perf 3Y	620.81%
Perf 5Y	167.89%
Perf 10Y	3576.57%
Recom	1.44
Target Price	411.48
Prev Close	363.76
Price	310.67
Change %	-14.59%

Consensus

Strong Buy

Avg. Price Target

$411.48

Implied Upside

+32.4%

Analysts17incl. previous ratings

Rating Distribution15 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 23, 2026	Initiated	RRoth Capital	Buy	$475	+52.9%
Sep 09, 2026	Resumed	UUBS	Buy	$435	+40.0%
Sep 08, 2026	Initiated	RRothschild & Co Redburn	Buy	$385	+23.9%
Jun 26, 2026	Resumed	BBernstein	Outperform	$310	-0.2%
Jun 12, 2026	Resumed	RRBC Capital Mkts	Outperform	$275	-11.5%
Jun 02, 2026	Resumed	WWolfe Research	Outperform	$260	-16.3%
Apr 14, 2026	Initiated	WWilliam Blair	Outperform
Jan 07, 2026	Initiated	CCitigroup	Buy	$300	-3.4%
Dec 02, 2025	Resumed	MMorgan Stanley	Overweight	$265	-14.7%
Oct 27, 2025	Upgrade	BBNP Paribas Exane	Underperform → Neutral	$172	-44.6%
Sep 22, 2025	Resumed	WWells Fargo	Equal Weight	$175	-43.7%
Mar 13, 2025	Initiated	RRBC Capital Mkts	Outperform	$251	-19.2%
Jan 23, 2025	Initiated	BBarclays	Overweight	$200	-35.6%
Jun 03, 2024	Resumed	JJefferies	Buy	$142	-54.3%
Apr 08, 2024	Resumed	CCraig Hallum	Buy	$117	-62.3%
Feb 20, 2024	Downgrade	RRaymond James	Strong Buy → Outperform	$68 → $85	-72.6%
Dec 29, 2023	Reiterated	BBTIG Research	Buy	$75 → $85	-72.6%
Dec 14, 2023	Initiated	GGuggenheim	Buy	$70	-77.5%
Dec 13, 2023	Initiated	WWolfe Research	Outperform	$70	-77.5%
Nov 13, 2023	Upgrade	RRaymond James	Outperform → Strong Buy	$68	-78.1%

Nov-06-26 12:46PM	Natera promotes Solomon Moshkevich to CEO (MedTech Dive) -14.59%
Nov-05-26 08:59PM	Natera Misses On The Bottom Line, But A 13% Revenue Beat, Third Guidance Raise And $6B 2029 Target Dominate The Quarter (Earnings Whispers) -6.97%
05:23PM	Natera: Q3 Earnings Snapshot (Associated Press)
03:06PM	Natera Announces Leadership Transition (Business Wire)
03:05PM	Natera Reports Third Quarter 2026 Financial Results (Business Wire)
06:00AM	Loading…
06:00AM	Signatera Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers (Business Wire)
Nov-04-26 06:00AM	Signatera in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability (Business Wire)
Nov-03-26 07:00AM	Medicare Expands Coverage for Signatera MRD Test in Hepatocellular Carcinoma (Business Wire)
Oct-29-26 12:24PM	Natera Enters Q3 With Signatera Momentum, Raised Guidance And A Stock Near Record Highs (Earnings Whispers)
08:00AM	Natera to Report its Third Quarter Results on November 5, 2026 (Business Wire)
04:03AM	Top Specialty Lab Stocks to Watch This Earnings Season, According to BTIG (Investing.com)
Oct-27-26 07:45AM	Signatera Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer (Business Wire)
Oct-26-26 07:00AM	Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight (Business Wire)
Oct-18-26 06:10PM	ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology (Business Wire)
Oct-15-26 12:46PM	Natera's Signatera MRD Test Named to TIME's List of the Best Inventions of 2026 (Business Wire)
07:30AM	Loading…
Oct-13-26 07:30AM	Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer (Business Wire)
Oct-09-26 10:19AM	Could You Have Seen The Run In Tempus AI Stock Coming? (Trefis)
08:41AM	Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test (InvestorsHub)
08:00AM	FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay (Business Wire)
Oct-07-26 08:00AM	Natera Announces Randomized, Signatera-Guided Interventional Study in Melanoma (Business Wire)
Oct-06-26 08:00AM	New Signatera Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists (Business Wire) -5.87%
Oct-05-26 10:05AM	Natera Launches Phase III MRD-Guided Breast Cancer Trial Using Signatera (InvestorsHub)
08:00AM	Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer (Business Wire)
Sep-22-26 01:50PM	NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak Whats Driving Investors Enthusiasm Today? (Stocktwits) +5.47%
08:00AM	Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (Business Wire)
Sep-18-26 06:00AM	Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM (Business Wire)
Sep-01-26 06:00AM	New Publication Establishes Strong Clinical Validation of Signatera for MRD Assessment in Lymphoma (Business Wire)
Aug-28-26 11:03AM	Natera and Susan G. Komen Announce National Partnership to Accelerate Progress Against Breast Cancer (Business Wire)
Aug-24-26 02:23PM	What Is Really Moving Tempus AI Stock Right Now? (Trefis)
Aug-17-26 11:55AM	13F Season: Where Wall Street's Smart Money is Betting (Zacks)
06:05PM	Loading…
Aug-14-26 06:05PM	Stanley Druckenmiller's Bold Second Quarter 2026 Move: Slashing Alcoa Corp at a -2. ... (GuruFocus.com)
Aug-12-26 06:00AM	Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude in Advanced Skin Cancers (Business Wire)
Aug-07-26 01:55PM	These Two Biotech Stocks Hit Fresh 52-Week Highs Today NTRA Clocks Best Day In Nearly 20 Months (Stocktwits) +21.37%
10:42AM	SpaceX's influence ripples across markets: AlphaCheck (Yahoo Finance)
01:09AM	Natera Inc (NTRA) (Q2 2026) Earnings Call Highlights: Record Volumes and Raised Guidance Signal ... (GuruFocus.com)
Aug-06-26 05:30PM	Natera: Q2 Earnings Snapshot (Associated Press)
Aug-05-26 06:00AM	Natera Submits Signatera to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (Business Wire)
Aug-03-26 04:06PM	Buffett-Inspired ETF Owns Berkshire, Apple, Amex and Generates 15% Yield (Barrons.com)
Jul-30-26 08:00AM	Natera to Report its Second Quarter Results on August 6, 2026 (Business Wire) +6.24%
Jul-22-26 06:00AM	Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study (Business Wire)
Jul-20-26 12:06PM	Cathie Wood Dumps $39 Million Worth of AMD Stock (GuruFocus.com)
Jul-16-26 06:35PM	Finalized MolDx LCD Includes Expanded Coverage for Nateras Prospera Portfolio (Business Wire)
08:13AM	Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It's Entering the U.S. (TSXV: SEGN) (FinanceWire)
Jul-13-26 12:52PM	Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group (GuruFocus.com)
Jul-10-26 08:57AM	Cathie Wood Dumps AMD, Doubles Down on Meta Stock (GuruFocus.com)
Jul-09-26 06:00AM	Natera Announces IVDR Certification for Signatera Across Multiple Cancers (Business Wire)
Jul-06-26 06:00AM	Signatera MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer (Business Wire)
Jul-02-26 06:41PM	CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology (Exec Edge)
Jul-01-26 06:02PM	When Multi-Cancer Blood Screens Could Finally Take Off (Barrons.com)
05:41PM	SkylineDxs Merlin CP-GEP Granted FDA Breakthrough Device Designation (Exec Edge)
Jun-29-26 06:00AM	Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer (Business Wire)
Jun-25-26 07:00AM	Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial (Business Wire)
Jun-24-26 05:00AM	Signatera Receives Regulatory Approval in Japan for Colorectal Cancer (Business Wire) +10.74%
Jun-23-26 06:00AM	NCCN Recommends ctDNA-MRD Testing Using Signatera Technology in Landmark Bladder Cancer Guideline Update (Business Wire)
Jun-18-26 06:00AM	Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress (Business Wire)
Jun-05-26 10:40AM	Healthcare Stocks Can Benefit From AI, Too. But That Isn't the Reason to Buy Them. (Barrons.com)
09:36AM	Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls (The Fly)
Jun-04-26 08:00AM	Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer (Business Wire)
Jun-03-26 08:00AM	Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors (Business Wire)
May-29-26 06:00AM	Natera Announces Collaboration with Diakonos Oncology for Signatera in Refractory Melanoma (Business Wire)
May-28-26 06:00AM	Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer (Business Wire) +5.33%
May-26-26 06:00AM	Natera to Launch Enhanced Panorama NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology (Business Wire)
May-21-26 05:05PM	Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology (Business Wire)
07:00AM	Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World (Business Wire)
May-20-26 04:51PM	Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder (IPO-Edge.com)
07:00AM	EXPAND Trial of Nateras Fetal Focus Single-Gene NIPT Surpasses >2,000 Patients Enrolled (Business Wire)
May-15-26 05:18PM	Stanley Druckenmiller Exits State Street Financial Select Sector SPDR ETF, Impacting Portfolio ... (GuruFocus.com) -5.36%
12:45PM	Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) (Business Wire)
12:01AM	Nateras Stronghold in Cancer Recurrence Tests Prompts Woods Ark to Expand Stake (The Daily Upside)
May-14-26 05:30AM	The Cancer Test That Wall Street Is Betting On (The Wall Street Journal)
May-07-26 05:22PM	Natera: Q1 Earnings Snapshot (Associated Press) -11.64%
04:05PM	Natera Reports First Quarter 2026 Financial Results (Business Wire)
May-06-26 09:31AM	Why The Dip In TEM Stock Is A Buying Window (Trefis)
Apr-30-26 08:00AM	Natera to Report its First Quarter Results on May 7, 2026 (Business Wire) +5.86%
Apr-23-26 12:33PM	SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases (Exec Edge)
Apr-22-26 09:00AM	Prospera Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT (Business Wire)
Apr-13-26 08:00AM	Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma (Business Wire)
Apr-09-26 06:00AM	Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents (Business Wire)
Apr-07-26 06:00AM	20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform (Business Wire)
Mar-31-26 06:00AM	SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery (Business Wire) +7.04%
Mar-16-26 06:00AM	Two Publications Highlight Clinical Utility of Signatera in Anal and Rectal Cancers (Business Wire) +5.23%
Mar-12-26 08:00AM	Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis (Business Wire)
08:00AM	MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 (PR Newswire)
Mar-09-26 12:41AM	3 Healthcare Stocks to Target This Week (StockStory)
Mar-04-26 07:10AM	Signatera Oncology Test Drives Natera's (NTRA) Growth (Insider Monkey)
Mar-03-26 03:35PM	Natera (NTRA) Stock Trades Up, Here Is Why (StockStory)
Feb-27-26 12:40PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
10:05AM	Signatera MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation (Business Wire)
12:07AM	Natera Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Natera Inc (NTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook ... (GuruFocus.com)
Feb-26-26 11:53PM	Natera, Inc. (NTRA) Announces Results From the SINERGY Trial (Insider Monkey)
06:45PM	Natera (NTRA) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:30PM	Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:58PM	Natera: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-24-26 10:28PM	Natera Earnings: What To Look For From NTRA (StockStory)
06:00AM	Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer (Business Wire)
Feb-23-26 09:15AM	Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-18-26 07:00PM	Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission (MarketBeat)
08:10AM	Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sheena Jonathan	CO-FOUNDER	Nov 02 '26	Sale	399.97	112	44,797	217,574	Nov 04 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 02 '26	Sale	400.02	748	299,214	2,116,928	Nov 04 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Nov 02 '26	Sale	400.05	341	136,416	167,880	Nov 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Nov 02 '26	Sale	409.77	3,419	1,400,994	101,323	Nov 04 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Nov 02 '26	Sale	400.01	302	120,804	195,276	Nov 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 02 '26	Sale	411.80	3,801	1,565,239	87,431	Nov 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Nov 03 '26	Sale	391.49	470	184,000	45,779	Nov 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Nov 02 '26	Sale	399.99	325	129,998	46,249	Nov 04 09:35 PM
MICHAEL BROPHY	Officer	Nov 03 '26	Proposed Sale	378.92	470	178,092		Nov 03 04:31 PM
STEVEN L CHAPMAN	Officer	Nov 02 '26	Proposed Sale	415.64	2,866	1,191,224		Nov 02 04:14 PM
JONATHAN SHEENA	DIRECTOR	Nov 02 '26	Proposed Sale	414.30	108	44,744		Nov 02 04:06 PM
MATTHEW RABINOWITZ	DIRECTOR	Nov 02 '26	Proposed Sale	414.30	722	299,125		Nov 02 04:06 PM
DANIEL RABINOWITZ	OFFICER	Nov 02 '26	Proposed Sale	414.30	330	136,719		Nov 02 04:05 PM
SOLOMON MOSHKEVICH	OFFICER	Nov 02 '26	Proposed Sale	414.30	405	167,792		Nov 02 04:05 PM
JOHN FESKO	OFFICER	Nov 02 '26	Proposed Sale	414.30	291	120,561		Nov 02 04:05 PM
STEVEN CHAPMAN	OFFICER	Nov 02 '26	Proposed Sale	414.30	903	374,113		Nov 02 04:05 PM
MICHAEL BROPHY	OFFICER	Nov 02 '26	Proposed Sale	414.30	313	129,676		Nov 02 04:04 PM
SOLOMON MOSHKEVICH	Officer	Nov 02 '26	Proposed Sale	411.13	3,000	1,233,380		Nov 02 04:03 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 30 '26	Sale	425.55	1,906	811,098	46,574	Oct 30 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 28 '26	Sale	426.46	1,178	502,372	48,480	Oct 30 09:35 PM
MICHAEL BROPHY	Officer	Oct 30 '26	Proposed Sale	436.00	1,906	831,016		Oct 30 04:21 PM
Sheena Jonathan	CO-FOUNDER	Oct 27 '26	Sale	406.00	291	118,146	217,873	Oct 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Oct 28 '26	Sale	426.34	187	79,726	217,686	Oct 29 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Oct 27 '26	Sale	406.00	1,718	697,508	2,117,676	Oct 29 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 28 '26	Sale	426.34	968	412,698	168,221	Oct 29 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 27 '26	Sale	406.00	884	358,904	169,189	Oct 29 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 28 '26	Sale	426.34	1,162	495,408	104,742	Oct 29 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 27 '26	Sale	406.00	1,010	410,060	105,904	Oct 29 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 28 '26	Sale	426.34	898	382,854	195,578	Oct 29 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 27 '26	Sale	406.00	781	317,086	196,476	Oct 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 28 '26	Sale	426.34	3,430	1,462,348	91,232	Oct 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 27 '26	Sale	406.00	2,264	919,184	94,662	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 28 '26	Sale	426.34	1,198	510,756	49,658	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 27 '26	Sale	406.00	781	317,086	50,856	Oct 29 09:35 PM
MICHAEL BROPHY	Officer	Oct 28 '26	Proposed Sale	410.82	1,178	483,946		Oct 28 05:58 PM
JONATHAN SHEENA	DIRECTOR	Oct 28 '26	Proposed Sale	410.82	191	78,467		Oct 28 04:19 PM
DANIEL RABINOWITZ	OFFICER	Oct 28 '26	Proposed Sale	410.82	988	405,890		Oct 28 04:18 PM
SOLOMON MOSHKEVICH	OFFICER	Oct 28 '26	Proposed Sale	410.82	1,185	486,822		Oct 28 04:18 PM
JOHN FESKO	OFFICER	Oct 28 '26	Proposed Sale	410.82	917	376,722		Oct 28 04:18 PM
STEVEN CHAPMAN	OFFICER	Oct 28 '26	Proposed Sale	410.82	3,499	1,437,459		Oct 28 04:17 PM
MICHAEL BROPHY	OFFICER	Oct 28 '26	Proposed Sale	410.82	1,222	502,022		Oct 28 01:14 PM
JONATHAN SHEENA	DIRECTOR	Oct 27 '26	Proposed Sale	404.90	287	116,206		Oct 27 04:14 PM
MATTHEW RABINOWITZ	DIRECTOR	Oct 27 '26	Proposed Sale	404.90	1,697	687,115		Oct 27 04:14 PM
DANIEL RABINOWITZ	OFFICER	Oct 27 '26	Proposed Sale	404.90	873	353,478		Oct 27 04:14 PM
SOLOMON MOSHKEVICH	OFFICER	Oct 27 '26	Proposed Sale	404.90	997	403,685		Oct 27 04:13 PM
JOHN FESKO	OFFICER	Oct 27 '26	Proposed Sale	404.90	771	312,178		Oct 27 04:13 PM
STEVEN CHAPMAN	OFFICER	Oct 27 '26	Proposed Sale	404.90	2,236	905,356		Oct 27 04:12 PM
MICHAEL BROPHY	OFFICER	Oct 27 '26	Proposed Sale	404.90	771	312,178		Oct 27 04:08 PM
Sheena Jonathan	CO-FOUNDER	Oct 21 '26	Sale	410.55	3,150	1,293,246	218,164	Oct 23 09:25 PM
Sheena Jonathan	Director	Oct 21 '26	Proposed Sale	410.55	9,450	3,879,737		Oct 21 01:09 PM
Sheena Jonathan	CO-FOUNDER	Oct 16 '26	Sale	402.47	1,500	603,710	8,250	Oct 20 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Oct 15 '26	Option Exercise	10.41	50,000	520,500	2,169,394	Oct 16 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Oct 15 '26	Sale	402.64	50,000	20,132,028	2,119,394	Oct 16 09:35 PM
MATTHEW RABINOWITZ	Director	Oct 15 '26	Proposed Sale	394.75	50,000	19,737,500		Oct 15 04:18 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 01 '26	Sale	413.31	1,273	526,144	96,926	Oct 02 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 01 '26	Sale	414.22	3,000	1,242,645	106,914	Oct 02 09:35 PM
STEVEN L CHAPMAN	Officer	Oct 01 '26	Proposed Sale	413.31	1,273	526,144		Oct 01 04:24 PM
SOLOMON MOSHKEVICH	Officer	Oct 01 '26	Proposed Sale	414.22	3,000	1,242,645		Oct 01 04:04 PM
Sheena Jonathan	CO-FOUNDER	Sep 23 '26	Sale	388.01	18,064	7,008,972	9,000	Sep 25 09:35 PM
Sheena Jonathan	Director	Sep 23 '26	Proposed Sale	387.55	21,064	8,163,402		Sep 23 10:58 AM
Sheena Jonathan	CO-FOUNDER	Sep 15 '26	Sale	350.07	6,000	2,100,431	224,464	Sep 17 09:35 PM
Sheena Jonathan	CO-FOUNDER	Sep 16 '26	Sale	354.19	3,150	1,115,714	221,314	Sep 17 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Sep 15 '26	Sale	347.19	50,000	17,359,280	2,125,394	Sep 16 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Sep 14 '26	Sale	334.76	50,000	16,737,977	2,175,394	Sep 16 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Sep 15 '26	Sale	350.01	2,000	700,014	0	Sep 16 09:35 PM
TINKERBELLE II TR U/A DTD 10/2	Officer	Sep 15 '26	Proposed Sale	350.01	2,000	700,015		Sep 15 04:53 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Sep 11 '26	Sale	327.97	50,000	16,398,267	2,225,394	Sep 11 09:35 PM
MATTHEW RABINOWITZ	Director	Sep 11 '26	Proposed Sale	326.14	200,000	65,228,000		Sep 11 04:28 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Sep 02 '26	Sale	326.89	15,160	4,955,713	110,859	Sep 03 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Sep 01 '26	Sale	320.73	3,000	962,194	126,019	Sep 03 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Sep 01 '26	Sale	320.99	1,698	545,041	98,199	Sep 03 09:05 PM
STEVEN L CHAPMAN	Officer	Sep 01 '26	Proposed Sale	320.99	1,698	545,041		Sep 01 04:08 PM
SOLOMON MOSHKEVICH	Officer	Sep 01 '26	Proposed Sale	320.73	3,000	962,194		Sep 01 04:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Aug 10 '26	Sale	321.53	6,517	2,095,411	197,257	Aug 28 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 10 '26	Sale	325.32	6,000	1,951,942	230,464	Aug 14 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Aug 07 '26	Sale	320.90	2,000	641,800	2,000	Aug 07 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 07 '26	Sale	315.66	9,150	2,888,325	236,464	Aug 07 09:35 PM
TINKERBELLE II TR U/A DTD 10/2	Officer	Aug 07 '26	Proposed Sale	320.90	2,000	641,800		Aug 07 05:42 PM
Sheena Jonathan	Director	Aug 07 '26	Proposed Sale	330.62	18,000	5,951,100		Aug 07 10:41 AM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Aug 04 '26	Sale	274.22	478	131,077	51,637	Aug 05 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Aug 03 '26	Sale	267.99	317	84,953	52,115	Aug 05 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Aug 03 '26	Sale	266.39	3,076	819,431	99,897	Aug 05 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Aug 03 '26	Sale	267.99	295	79,057	183,774	Aug 05 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Aug 03 '26	Sale	265.58	3,410	905,627	129,019	Aug 05 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Aug 03 '26	Sale	267.99	334	89,508	170,073	Aug 05 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Aug 03 '26	Sale	267.99	731	195,900	2,275,394	Aug 05 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 03 '26	Sale	267.99	109	29,211	245,614	Aug 05 09:35 PM
MICHAEL BROPHY	Officer	Aug 04 '26	Proposed Sale	270.36	478	129,232		Aug 04 04:36 PM
JONATHAN SHEENA	OFFICER	Aug 03 '26	Proposed Sale	267.76	108	28,918		Aug 03 04:22 PM
MATTHEW RABINOWITZ	OFFICER	Aug 03 '26	Proposed Sale	267.76	722	193,323		Aug 03 04:22 PM
DANIEL RABINOWITZ	OFFICER	Aug 03 '26	Proposed Sale	267.76	330	88,361		Aug 03 04:22 PM
SOLOMON MOSHKEVICH	OFFICER	Aug 03 '26	Proposed Sale	267.76	405	108,443		Aug 03 04:21 PM
JOHN FESKO	OFFICER	Aug 03 '26	Proposed Sale	267.76	292	78,186		Aug 03 04:21 PM
STEVEN CHAPMAN	OFFICER	Aug 03 '26	Proposed Sale	267.76	1,167	312,476		Aug 03 04:21 PM
MICHAEL BROPHY	OFFICER	Aug 03 '26	Proposed Sale	267.76	313	83,809		Aug 03 04:20 PM
STEVEN L CHAPMAN	Officer	Aug 03 '26	Proposed Sale	265.40	1,894	502,668		Aug 03 04:18 PM
SOLOMON MOSHKEVICH	Officer	Aug 03 '26	Proposed Sale	265.25	3,000	795,751		Aug 03 04:09 PM
Sheena Jonathan	CO-FOUNDER	Jul 27 '26	Sale	260.49	288	75,021	245,914	Jul 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jul 28 '26	Sale	254.07	191	48,527	245,723	Jul 29 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jul 27 '26	Sale	260.49	1,718	447,523	2,276,125	Jul 29 09:35 PM

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Co-Founder & Executive ChairmanDr. Matthew Rabinowitz Ph.D.

CEO & DirectorMr. Steven Leonard Chapman

President & Chief Business OfficerMr. John Fesko

Chief Financial OfficerMr. Michael B. Brophy M.B.A.

President of Clinical DiagnosticsMr. Solomon Moshkevich M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTRA

Natera Inc

Upgrade your Finviz experience